US-based Spero Therapeutics LLC closed a $30 million Series A financing round led by Lundbeckfond Ventures. Further new investors are Merck Research Ventures and The Kraft Group. All existing investors participated as well. The company will use the proceeds to advance its pipeline of novel treatments against severe bacterial infections, including those that are highly resistant to even the most potent existing antibiotics. Spero’s lead Potentiator program, which is designed to increase the potency of existing anti-infectives, is expected to reach the clinical stage in 2016. Further programs include an anti-virulence approach partnered with Roche and a series of innovative compounds against serious hospital-acquired infections licensed from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a branch of the Helmholtz Centre for Infection Research (HZI).
For further information see: <link http: sperotherapeutics.com news press-releases spero-completes-30-million-financing _blank external-link-new-window>Spero’s press release
